AN2 Therapeutics Inc
Veridion Score
Composite trend over time
Why is ANTX moving today?
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology. Product candidate AN2-502998 Epetraborole.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for ANTX.
ANTX insider activity
AN2 Therapeutics Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$55K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-02 | 2026-05-29 | Williams Sarah Joanne | Insider | sell | $4.43 | 265 | 66,583 | $1K | SEC Form 4 |
| 2026-03-05 | 2026-03-03 | Williams Sarah Joanne | Insider | sell | $1.06 | 327 | 66,848 | $347 | SEC Form 4 |
| 2026-01-07 | 2026-01-06 | Day Lucy | Insider | sell | $1.01 | 5,512 | 75,363 | $6K | SEC Form 4 |
| 2026-01-07 | 2026-01-06 | Prior Stephen David | Insider | sell | $1.01 | 2,858 | 59,086 | $3K | SEC Form 4 |
| 2026-01-07 | 2026-01-06 | Eizen Joshua M | Insider | sell | $1.01 | 6,931 | 152,499 | $7K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 7 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moANTX contract awards, year to date.
Public federal awards linked to this ticker.
ANTX lobbying filings, year to date.
Registered lobbying filings matched to AN2 Therapeutics Inc.